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Camilo E Fadul1,2,3*, Jan L Fisher1, Thomas H Hampton1 and Marc S Ernstoff1,2,3May 8, 2014
Pedro Romero, M.D.
Editor-in-Chief
Journal for ImmunoTherapy of Cancer
Dear Dr. Romero,
We read with interest the work by Olin and collaborators
published in the Journal for ImmunoTherapy of Cancer
under the title “Vaccination with dendritic cells loaded with
allogeneic brain tumor cells for recurrent malignant brain
tumors induces a CD4 + IL17+ response” [1]. Immune ther-
apy trials for malignant brain tumors are challenging to
undertake and there are many factors, including the high
expense per patient which limits the number of patients en-
rolled, hence curtailing the ability to demonstrate that the
intervention improves clinical outcomes. Furthermore, the
baseline immune competence of patients with gliomas is
heterogeneous and is an important variable in determining
who will benefit from this therapeutic modality. Assessment
of immune markers before treatment with immunotherapy
which could reliably predict response is highly desirable,
since patients unlikely to benefit could be considered for al-
ternate clinical trials.
Profiling the immune cell populations in peripheral
blood by flow cytometry is a potentially useful tool, and
hierarchical clustering analysis of the multiple cell popu-
lations measured may provide a distinct and comprehen-
sive overview of the immune status [2]. Olin et al. use
this methodology to separate patients with brain tumors
who had stable or progressive disease after being treated
with dendritic cells loaded with allogeneic tumor. We
would like to bring to the attention of the authors and
readership that in our 2011 publication, we applied hier-
archical clustering to functional immune assay measures
of antigen specific response to treatment with autolo-
gous tumor lysate loaded DC vaccination in a cohort of
glioblastoma patients [3]. The shift of immune response
measures discerned 2 groups of patients that correlated
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unless otherwise stated.Successful use of hierarchical clustering analysis of mul-
tiple immune measures as a prognostic and predictive
marker in patients with gliomas first reported by us and
confirmed by Olin et al., serves as a proof of principle. A
substantially larger study using supervised classification
techniques to identify the key prognostic factors, will allow
validation of a prediction system. Integrated biomarkers
that are able to more accurately and reliably quantify im-
mune competence are needed to be able to do clinical tri-
als enriched for individuals likely to benefit from immune
therapy.
Sincerely,
Camilo E. Fadul, MD
Jan L. Fisher, MS
Thomas H. Hampton, MS
Marc S. Ernstoff, MD
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